Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Advani, R., Saba, H. I., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Sikic, B. I., Davis, E., Paietta, E., Litchman, M., Greenberg, P. W B SAUNDERS CO. 1997: 2260

View details for Web of Science ID A1997YG42402256